Literature DB >> 24600513

Role of 3'-untranslated region translational control in cancer development, diagnostics and treatment.

Andrii Vislovukh1, Thaiz Rivera Vargas1, Anna Polesskaya1, Irina Groisman1.   

Abstract

The messenger RNA 3'-untranslated region (3'UTR) plays an important role in regulation of gene expression on the posttranscriptional level. The 3'UTR controls gene expression via orchestrated interaction between the structural components of mRNAs (cis-element) and the specific trans-acting factors (RNA binding proteins and non-coding RNAs). The crosstalk of these factors is based on the binding sequences and/or direct protein-protein interaction, or just functional interaction. Much new evidence that has accumulated supports the idea that several RNA binding factors can bind to common mRNA targets: to the non-overlapping binding sites or to common sites in a competitive fashion. Various factors capable of binding to the same RNA can cooperate or be antagonistic in their actions. The outcome of the collective function of all factors bound to the same mRNA 3'UTR depends on many circumstances, such as their expression levels, affinity to the binding sites, and localization in the cell, which can be controlled by various physiological conditions. Moreover, the functional and/or physical interactions of the factors binding to 3'UTR can change the character of their actions. These interactions vary during the cell cycle and in response to changing physiological conditions. Abnormal functioning of the factors can lead to disease. In this review we will discuss how alterations of these factors or their interaction can affect cancer development and promote or enhance the malignant phenotype of cancer cells. Understanding these alterations and their impact on 3'UTR-directed posttranscriptional gene regulation will uncover promising new targets for therapeutic intervention and diagnostics. We will also discuss emerging new tools in cancer diagnostics and therapy based on 3'UTR binding factors and approaches to improve them.

Entities:  

Keywords:  3’-untranslated region; Cancer; MicroRNAs; RNA binding proteins; Translational control

Year:  2014        PMID: 24600513      PMCID: PMC3942541          DOI: 10.4331/wjbc.v5.i1.40

Source DB:  PubMed          Journal:  World J Biol Chem        ISSN: 1949-8454


  220 in total

Review 1.  The widespread regulation of microRNA biogenesis, function and decay.

Authors:  Jacek Krol; Inga Loedige; Witold Filipowicz
Journal:  Nat Rev Genet       Date:  2010-07-27       Impact factor: 53.242

2.  let-7 microRNA reduces tumor growth.

Authors:  Frank Slack
Journal:  Cell Cycle       Date:  2009-06-15       Impact factor: 4.534

3.  A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors.

Authors:  P Mathijs Voorhoeve; Carlos le Sage; Mariette Schrier; Ad J M Gillis; Hans Stoop; Remco Nagel; Ying-Poi Liu; Josyanne van Duijse; Jarno Drost; Alexander Griekspoor; Eitan Zlotorynski; Norikazu Yabuta; Gabriella De Vita; Hiroshi Nojima; Leendert H J Looijenga; Reuven Agami
Journal:  Cell       Date:  2006-03-24       Impact factor: 41.582

4.  Frequent downregulation of miR-34 family in human ovarian cancers.

Authors:  David C Corney; Chang-Il Hwang; Andres Matoso; Markus Vogt; Andrea Flesken-Nikitin; Andrew K Godwin; Aparna A Kamat; Anil K Sood; Lora H Ellenson; Heiko Hermeking; Alexander Yu Nikitin
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

5.  Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia.

Authors:  Konstantinos J Mavrakis; Andrew L Wolfe; Elisa Oricchio; Teresa Palomero; Kim de Keersmaecker; Katherine McJunkin; Johannes Zuber; Taneisha James; Aly A Khan; Christina S Leslie; Joel S Parker; Patrick J Paddison; Wayne Tam; Adolfo Ferrando; Hans-Guido Wendel
Journal:  Nat Cell Biol       Date:  2010-02-28       Impact factor: 28.824

6.  Identification of an mRNP complex regulating tumorigenesis at the translational elongation step.

Authors:  George S Hussey; Arindam Chaudhury; Andrea E Dawson; Daniel J Lindner; Charlotte R Knudsen; Matthew C J Wilce; William C Merrick; Philip H Howe
Journal:  Mol Cell       Date:  2011-02-18       Impact factor: 17.970

7.  Mammalian GLD-2 homologs are poly(A) polymerases.

Authors:  Jae Eun Kwak; Liaoteng Wang; Scott Ballantyne; Judith Kimble; Marvin Wickens
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-30       Impact factor: 11.205

8.  The let-7 microRNA reduces tumor growth in mouse models of lung cancer.

Authors:  Aurora Esquela-Kerscher; Phong Trang; Jason F Wiggins; Lubna Patrawala; Angie Cheng; Lance Ford; Joanne B Weidhaas; David Brown; Andreas G Bader; Frank J Slack
Journal:  Cell Cycle       Date:  2008-03-03       Impact factor: 4.534

9.  Suppression of non-small cell lung tumor development by the let-7 microRNA family.

Authors:  Madhu S Kumar; Stefan J Erkeland; Ryan E Pester; Cindy Y Chen; Margaret S Ebert; Phillip A Sharp; Tyler Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

10.  Cell-cycle control of microRNA-mediated translation regulation.

Authors:  Shobha Vasudevan; Yingchun Tong; Joan A Steitz
Journal:  Cell Cycle       Date:  2008-03-25       Impact factor: 4.534

View more
  17 in total

1.  miR-99a directly targets the mTOR signalling pathway in breast cancer side population cells.

Authors:  Z Yang; Y Han; K Cheng; G Zhang; X Wang
Journal:  Cell Prolif       Date:  2014-10-27       Impact factor: 6.831

2.  miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1.

Authors:  Xiaoli Yuan; Rongjun Ma; Shiwei Yang; Li Jiang; Zhen Wang; Zunmin Zhu; Hongwei Li
Journal:  Cell Cycle       Date:  2019-06-20       Impact factor: 4.534

3.  MicroRNA Regulating Glutathione S-Transferase P1 in Prostate Cancer.

Authors:  Savita Singh; Girish C Shukla; Sanjay Gupta
Journal:  Curr Pharmacol Rep       Date:  2015-04-01

4.  microRNA-141 inhibits cell proliferation and invasion and promotes apoptosis by targeting hepatocyte nuclear factor-3β in hepatocellular carcinoma cells.

Authors:  Li Lin; Hongwei Liang; Yanbo Wang; Xiaomao Yin; Yanwei Hu; Jinlan Huang; Tingyu Ren; Hui Xu; Lei Zheng; Xi Chen
Journal:  BMC Cancer       Date:  2014-11-25       Impact factor: 4.430

Review 5.  Molecular Mechanisms and Pathways as Targets for Cancer Prevention and Progression with Dietary Compounds.

Authors:  Nagisa Nosrati; Marica Bakovic; Gopinadhan Paliyath
Journal:  Int J Mol Sci       Date:  2017-09-25       Impact factor: 5.923

6.  Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma.

Authors:  Jelena Kresoja-Rakic; Merve Sulemani; Michaela B Kirschner; Manuel Ronner; Glen Reid; Steven Kao; Beat Schwaller; Walter Weder; Rolf A Stahel; Emanuela Felley-Bosco
Journal:  Front Genet       Date:  2017-05-29       Impact factor: 4.599

Review 7.  Role of micro-RNAs in drug resistance of multiple myeloma.

Authors:  Jahangir Abdi; Hou Jian; Hong Chang
Journal:  Oncotarget       Date:  2016-09-13

Review 8.  Complex interactomes and post-translational modifications of the regulatory proteins HABP4 and SERBP1 suggest pleiotropic cellular functions.

Authors:  Carolina Colleti; Talita Diniz Melo-Hanchuk; Flávia Regina Moraes da Silva; Ângela Saito; Jörg Kobarg
Journal:  World J Biol Chem       Date:  2019-11-21

9.  Deep Learning Improves Pancreatic Cancer Diagnosis Using RNA-Based Variants.

Authors:  Ali Al-Fatlawi; Negin Malekian; Sebastián García; Andreas Henschel; Ilwook Kim; Andreas Dahl; Beatrix Jahnke; Peter Bailey; Sarah Naomi Bolz; Anna R Poetsch; Sandra Mahler; Robert Grützmann; Christian Pilarsky; Michael Schroeder
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

10.  CFIm25-regulated lncRNA acv3UTR promotes gastric tumorigenesis via miR-590-5p/YAP1 axis.

Authors:  Kai Liu; Ben-Jun Wang; WeiWei Han; Chun-Hua Chi; Chao Gu; Yu Wang; Xiaohai Fu; Wei Huang; Zhiguo Liu; Xilin Song
Journal:  Oncogene       Date:  2020-02-17       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.